Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc Appoints Jack A. Khattar as Chief Executive Officer of Supernus, Inc
Indivior Pharmaceuticals and Artemis Merger Sub agreed to merge with Supernus Pharmaceuticals, with Supernus as the surviving company and a wholly owned subsidiary of Indivior. After the deal, Indivior will be renamed Supernus. Jack A. Khattar will become CEO and CFO Timothy C. Dec will serve as CFO, effective at closing.
How this was made
The 30-second read
Why it matters
For traders, the key actionable items are the confirmed merger structure, governance composition, and named executive roles (Jack A. Khattar as CEO, Timothy C. Dec as CFO). However, the text lacks deal price and other terms that typically drive the largest repricing.
Market read
This is a confirmed merger framework with leadership and board composition details, which can drive near-term M&A positioning in both the acquirer and target stocks.
What to watch
Board split and CEO/CFO assignments can be interpreted as integration planning, but investors will likely wait for the full merger terms, synergies, and any regulatory pathway details not included here.
Background
The article states that Indivior and Artemis Merger Sub entered an Agreement and Plan of Merger with Supernus, with Supernus surviving and becoming a wholly owned subsidiary of Indivior; the combined company will be renamed Supernus, Inc.
Ticker impact
Indivior is the acquirer in a merger agreement where its Merger Sub will merge with Supernus, with Indivior renaming to Supernus.
Near-term repricing possible on deal terms and governance/management changes, but magnitude depends on disclosed economics not included here.
The article discloses a merger framework, board composition, and executive assignments, which are typically market-moving, but it omits key deal economics and timing details.
Supernus is the target in an agreement where Merger Sub merges into Supernus, making Supernus the surviving company and a wholly owned subsidiary of Indivior.
Acquisition headlines often support the target stock, but the direction and size depend on the offer price and conditions not provided here.
The text confirms a merger agreement and leadership roles, but provides no consideration, valuation, or regulatory/closing milestones.
Market effects
Could shift competitive and pipeline expectations in substance-use disorder pharma, especially around long-acting injectables and nalmefene products.
Primarily US-listed pharma sentiment; limited direct regional spillover implied by the text.
Global SUD market positioning may be affected, but the article provides no geographic or regulatory specifics.
Counterpoint
Without disclosed merger consideration, termination fees, or closing conditions, the market may discount the headline and focus on execution risk and valuation fairness.
Key entities
- acquirerIndivior Pharmaceuticals, Inc.
Party to the merger agreement via Artemis Merger Sub; combined company will be renamed Supernus, Inc.
- targetSupernus Pharmaceuticals, Inc.
Surviving company in the merger; becomes wholly owned subsidiary of Indivior; CEO and CFO roles specified for combined company.
- merger vehicleArtemis Merger Sub Inc.
Merger Sub merges with and into Supernus under the agreement.
- executiveJack A. Khattar
Named CEO and board member of the combined company.
- executiveTimothy C. Dec
Named CFO of the combined company.
